OTC naloxone nasal spray to cost about as much as the brand-name, prescription version
The FDA recently approved multiple over-the-counter (OTC) versions of the nasal spray that can reverse opioid overdoses, promising new low-cost competitors. But now a nonprofit that won one of the approvals says its spray will cost about the same, if not slightly more, than the brand-name prescription version.
The nonprofit Harm Reduction Therapeutics, or HRT, which has been funded with $20 million from the now-bankrupt opioid seller Purdue Pharma, confirmed to Endpoints News that its OTC naloxone nasal spray known as RiVive will be available in Jan. 2024 at a cost of $36.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
